GlassScriptPhysician profile
Danielle V Seier
NPI 1700469848
$2,953.33
in general payments reported to CMS, 2019-2025
17 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $465 · 2023: $1,265 · 2024: $988 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $705.40 | 2022-2024 | |
| Ucb, INC. | $546.54 | 2022-2024 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $515.17 | 2022-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $424.52 | 2022-2025 | |
| Livanova USA, INC. | $152.89 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $117.72 | 2025 | Breztri |
| Sumitomo Pharma America, INC. | $113.25 | 2023-2024 | Aptiom |
| Eisai INC. | $66.21 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $53.69 | 2024 | Motpoly Xr |
| Pfizer INC. | $51.22 | 2023-2024 | |
| Nobelpharma America, LLC | $49.86 | 2022-2023 | |
| Owp Pharmaceuticals, INC. | $31.94 | 2023-2024 | Subvenite, Lamotrigine |
| Azurity Pharmaceuticals, INC. | $31.72 | 2023-2024 | Zonisade, Eprontia |
| Aprecia Pharmaceuticals, LLC | $30.62 | 2023 | Spritam |
| Catalyst Pharmaceuticals, INC. | $27.91 | 2023-2024 | Fycompa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $19.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Seier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.